Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.80 · Revenue $0.00 · 5 analysts
Est. EPS $-0.93 · Revenue $25.71M · 4 analysts
Est. EPS $-3.23 · Revenue $22.50M · 6 analysts
Est. EPS $1.58 · Revenue $124.17M · 1 analysts
EPS $-0.71 · Revenue $0.00
EPS $-0.68 · Revenue $0.00
EPS $-2.31 · Revenue $0.00
EPS $-0.65 · Revenue $0.00
EPS $-0.50 · Revenue $0.00
EPS $-0.44 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-77.6M | -114.7% | -5.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-37.2M | -26.5% | — |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.1% | -84.9% | — |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 50.02x | +105.8% | -0.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $780.6M | +413.1% | -2.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.31 vs -2.18 | -5.8% | -0.71 vs -0.80 | +11.0% |
| Revenue Surprise | $0 vs $16.7M | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Chuang Hao-Yuan | director, officer: Chief Financial Officer | American depositary share | D | 144 | $180.00 |
| Aug 12, 2026 | Chuang Hao-Yuan | director, officer: Chief Financial Officer | American depositary share | D | 223 | $180.57 |
| Aug 12, 2026 | Lin Yu-Hsin | director, officer: Chief Executive Officer | American depositary share | D | 142 | $180.00 |
| Aug 12, 2026 | Lin Yu-Hsin | director, officer: Chief Executive Officer | American depositary share | D | 223 | $180.57 |
| Jun 18, 2026 | Scholl Hendrik Peter | officer: Chief Medical Officer | American depositary share | D | 96 | $143.90 |
Operator: Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio second Quarter 26 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please raise your hand. If you have dialed in to today's call, please press 9 to raise your hand. And 6 to unmute. I will now hand the conference over to Julie Fallon. Please go ahead. Julie Fallon: Thank you for joining us. On the call today are Dr. Tom Lin, Chairman and CEO of Belite Bio, Dr. Hendrik Scholl, Chief Medical Officer; Dr. Nathan L. Mata, Chief Scientific Officer and Hao-Yuan Chuang, Chief Financial Officer. Before we begin, let me point out that we will be making forward looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today we will be discussing certain non GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today. And now I will turn the call over to Dr. Lin. Dr. Lin? Yu-Hsin Lin: Thank you, Julie. Good afternoon, everyone. Thank you for joining our second quarter 26 financial results and corporate update call. The first half of this year has been both exciting and deeply productive for Belite Bio. As we rapidly approach a potential regulatory approval of tinlarebant for Stargardt disease in the US. We are very pleased to announce that the FDA has accepted our new drug application for tinlarebant with priority review. And establishing a PDUFA date of 02/12/2027. We believe this reflects the strength, consistency, and depth of clinical data generated across our development program. In parallel with our precommercial preparations, we remain highly engaged with the medical and patient communities. The enthusiasm we are seeing underscores the profound need for a new treatment paradigm in Stargardt disease. This quarter, we presented our Phase 3 Dragon study results at 4 medical conferences across 4 countries. Including the recent American Society of Retinal Specialists, ASRS, annual. At ASRS, we presented new secondary endpoint data demonstrating subjects treated with tinlarebant showed a halt to a slightly decreased QAF values, decreased by approximately 2%. At month 25 compared to baseline. In contrast, subjects in the placebo group exhibited an approximately 20% increase in QAF values over the same period. Quantitative autofluorescence or QAF is a marker of toxic bisretinoid accumulation. A key driver of retinal degeneration in Stargardt disease. The prevention or reduction of QAF strongly aligns with tinlarebant's mechanism of action. Reinforcing its potential to halt or slow lesion growth. Looking ahead, we remain confident in our data. Our science, the transformative potential of …
| Name | Title | Gender | Year Born | Status |
|---|---|---|---|---|
Hendrik Scholl | Chief Medical Officer | — | 1969 | Active |
Nathan L. Mata | Chief Scientific Officer | — | 1966 | Active |
Yu-Hsin Lin | Chairman of the Board of Directors & Chief Executive Officer | — | 1978 | Active |
Hao-Yuan Chuang | Chief Financial Officer & Director | Male | 1984 | Active |
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00 – 9:30 a.m. ET.
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress being held on August 28-30, 2026, in Gold Coast, Australia.
Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript
Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the application priority review. The agency set a Prescription Drug User Fee Act action date of Feb. 12, 2027.
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2026, and provided a business update.
